Applied DNA Sciences Restructures to Focus on Synthetic DNA Manufacturing

Applied DNA Sciences, Inc. has announced a strategic restructuring, focusing exclusively on its synthetic DNA manufacturing arm, LineaRx. The company has reduced its workforce by 27% and ceased operations at Applied DNA Clinical Labs, aiming to reduce costs and allocate resources to LineaRx. This move is designed to enhance LineaRx's capabilities, expand service offerings, and pursue strategic partnerships.

LineaRx, a subsidiary of Applied DNA, is poised to advance in the enzymatic production of synthetic DNA used in DNA- and RNA-based medicines. The restructuring is expected to yield a projected 23% reduction in annual payroll costs, offset by $300,000 in one-time charges.

Since December 2024, Applied DNA has exited non-core operations and reduced headcount by 39%. The company held $4.8 million in cash as of May 2025. The focus on LineaRx aligns resources towards customer acquisition and market expansion in synthetic DNA manufacturing.